Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma
Kouya Shiraishi, Takashi Kohno(Gunma University), Yukihide Momozawa(RIKEN Center for Integrative Medical Sciences), Kimihiro Shimizu(Shinshu University), Yataro Daigo(The University of Tokyo), Johji Inazawa(Shanghai Institute for Science of Science), Katsuya Tsuchihara(Chiba Cancer Center), Hiroshi Nokihara(Tokushima University Hospital), Akiteru Goto(Akita University), Tomoyuki Yokose(Kanagawa Prefectural Hospital Organization), Yukio Watanabe(Juntendo University), Koh Furuta(Teikyo University Chiba Medical Center), Yasushi Goto(Tennessee Oncology), Yukinori Okada(RIKEN Center for Integrative Medical Sciences), Kōichi Goto(National Cancer Center Hospital East), Akira Saito(StaGen (Japan)), Fumihiko Matsuda(Kyoto University), Atsushi Takano(Shiga University of Medical Science), Masahiro Tsuboi(National Cancer Center Hospital East), Toshiteru Nagashima(Gunma University Hospital), Yoshihiro Minamiya(Akita University), Keitaro Matsuo(Aichi Cancer Center), Michiaki Kubo(RIKEN Center for Integrative Medical Sciences), Yohei Miyagi(Kanagawa Cancer Center), Yoichi Ohtaki(Gunma University Hospital), Kuniko Sunami(Tokyo National Hospital), Tomoyuki Hishida(National Cancer Center Hospital East), Kazuhiro Imai(Akita University), Motonobu Saito(Fukushima Medical University), Yuichiro Ohe(National Cancer Center), Atsushi Takahashi(Fukushima Medical University), Yusuke Nakamura(National Institute of Biomedical Innovation, Health and Nutrition), Daichi Maeda(Garvan Institute of Medical Research), Jun Yokota(Fukushima Medical University), Akihiko Yoshida(Tokyo National Hospital), Hideo Kunitoh(Japanese Red Cross Medical Center), Teruhiko Yoshida(National Cancer Centre Japan), Yoko Shimada, Kazumi Tanaka(Gunma University Hospital), Koji Tsuta(Kansai Medical University), Haruhiko Nakayama, Hiromi Sakamoto(National Cancer Centre Japan), Shingo Matsumoto(National Cancer Center Hospital East), Shun-ichi Watanabe(Tokyo National Hospital), Kyota Ashikawa
Cited by 58
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k